The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung…
in Health
Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations
